Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Japanese Journal of Clinical Oncology|March 17, 2022
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari studyHidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, et al.
Future Oncology (London, England)|September 16, 2024
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancerNicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast CancerVeronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2026
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trialKomal Jhaveri, Hope S Rugo, Javier Cortés, et al.
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
The New England Journal of Medicine|May 31, 2023
Capivasertib in Hormone Receptor-Positive Advanced Breast CancerNicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
The Lancet. Oncology|August 30, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialMafalda Oliveira, Hope S Rugo, Sacha J Howell, et al.
International Journal of Clinical Oncology|March 24, 2023
Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro FujiiYoshihiko Maehara, Eiji Oki, Mitsuhiko Ota, et al.
Nature Medicine|October 8, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialShanu Modi, William Jacot, Hiroji Iwata, et al.
Breast Cancer (Tokyo, Japan)|August 1, 2025
A retrospective multi-center cohort study investigating safety of sentinel lymph node biopsy for axillary staging in clinical T3-4c breast cancerSayaka Kuba, Yasuaki Sagara, Hiroshi Yano, et al.
Pageof 16